Exelixis
EXEL
#2109
Rank
ยฃ5.74 B
Marketcap
ยฃ20.13
Share price
-1.53%
Change (1 day)
15.14%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of June 2024 : ยฃ0.15 B

According to Exelixis's latest financial reports the company's total debt is ยฃ0.15 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31ยฃ0.14 B-5.15%
2022-12-31ยฃ0.15 B314.92%
2021-12-31ยฃ37.88 M5.36%
2020-12-31ยฃ35.95 M-0.62%
2019-12-31ยฃ36.17 M209.48%
2018-12-31ยฃ11.69 M5.77%
2017-12-31ยฃ11.05 M-92.79%
2016-12-31ยฃ0.15 B-45.6%
2015-12-31ยฃ0.28 B22.86%
2014-12-31ยฃ0.22 B9.06%
2013-12-31ยฃ0.21 B1.27%
2012-12-31ยฃ0.20 B77.78%
2011-12-31ยฃ0.11 B-13.81%
2010-12-31ยฃ0.13 B173.18%
2009-12-31ยฃ49.59 M-39.23%
2008-12-31ยฃ81.61 M34.11%
2007-12-31ยฃ60.85 M-2.01%
2006-12-31ยฃ62.1 M-28.05%
2005-12-31ยฃ86.31 M12.36%
2004-12-31ยฃ76.82 M22.65%
2003-12-31ยฃ62.63 M35.84%
2002-12-31ยฃ46.11 M36.6%
2001-12-31ยฃ33.75 M237%
2000-12-31ยฃ10.01 M21.69%
1999-12-31ยฃ8.23 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
ยฃ16.33 B 10,725.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ19.40 B 12,757.84%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ28.79 B 18,983.21%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ41.14 B 27,172.41%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ47.73 B 31,536.17%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ31.61 B 20,853.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ52.32 B 34,582.38%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ2.71 M-98.20%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ29.47 M-80.47%๐Ÿ‡บ๐Ÿ‡ธ USA